Filing identity and reporting period
Source mismatch: The request identifies Tuhura Biosciences, Inc. and 2015 Q4, but the supplied filing is DelMar Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended June 30, 2016, filed September 12, 2016. This summary reflects the supplied DelMar filing, not a Tuhura filing or a 2015 quarterly report.
Business context
DelMar was a clinical-stage cancer drug developer, focused primarily on VAL-083 for glioblastoma (GBM). VAL-083 was not approved in the U.S.; it was approved in China for chronic myelogenous leukemia and lung cancer, where DelMar held certain commercial rights. The company reported no product revenue and had not commercialized its candidate.
Financial results and liquidity
| Metric (US$) | FY ended June 30, 2016 | FY ended June 30, 2015 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | 3,360,878 | 2,555,754 |
| General and administrative expense | 2,853,140 | 2,168,899 |
| Net loss | 8,864,864 | 4,347,767 |
| Basic and diluted loss per share | 0.81 | 0.46 |
| Cash used in operating activities | 5,145,814 | 3,853,069 |
| Cash and cash equivalents at year-end | 6,157,264 | 1,754,433 |
| Working capital | 5,692,336 | 1,722,336 |
| Total assets | 6,355,799 | 2,575,421 |
| Stockholders’ equity (deficit) | 4,858,778 | (821,490) |
Operating cash outflow rose 33% year over year. Financing provided net cash of $9.57 million, including $6.54 million net proceeds from Series B preferred shares, $2.45 million from a public offering, and $579,309 from warrant exercises. The filing reports no conventional borrowing balance in the balance sheet; it lists a $693,700 derivative liability and a $175,875 stock-option liability. No margins are meaningful because the company had no reported revenue.
Management cited a $32.24 million accumulated deficit and substantial ongoing funding needs. The audited statements include liquidity-risk disclosure; management believed available resources, including $257,110 from post-year-end warrant exercises, would fund operations beyond twelve months, but further financing remained necessary and uncertain. The company reported no off-balance-sheet arrangements.
Material changes and unusual items
- Net loss more than doubled, while R&D and G&A expenses each increased about 32%, reflecting clinical-trial activity, Phase III preparation, professional fees, and higher noncash compensation.
- Loss included a $1.96 million warrant fair-value loss and a $295,456 loss related to warrant-term changes. These noncash valuation items can make reported results volatile.
- The company raised approximately $7.2 million gross through Series B preferred stock. The shares carry a 9% annual cumulative dividend payable in common shares, convert at 2.5 common shares per preferred share, and include a low-single-digit royalty arrangement on qualifying product sales. The filing also reports a common-stock dividend valued at $238,326.
- A $100,868 out-of-period adjustment increased stock-based compensation and the stock-option liability; management described its effect on current and prior periods as not material.
- DelMar completed a 1-for-4 reverse stock split in May 2016, and its common stock began trading on Nasdaq in July 2016.
Development outlook, commentary, and risks
- DelMar selected a 40 mg/m² dosing regimen for proposed further GBM testing. In its Phase I/II refractory-GBM study, it reported median survival of 8.35 months among 22 patients receiving an assumed therapeutic dose after bevacizumab failure. The company cautioned that the study was small and uncontrolled; median progression-free survival was 1.2 months.
- Management planned a randomized Phase III study in refractory GBM, conditional on FDA guidance and funding. It also described planned Phase II studies in newly diagnosed, high-MGMT GBM and first-recurrence GBM with MD Anderson, subject to study arrangements and initiation.
- Clinical evidence remained preliminary. Reported dose-limiting toxicity was primarily blood-cell suppression, particularly thrombocytopenia. VAL-083 remained investigational outside China, and regulatory approval, efficacy, safety, manufacturing readiness, and commercial success were uncertain.
- Additional risks included dependence on a single product candidate, need for further capital and potential shareholder dilution, reliance on third-party clinical and manufacturing partners, competitive pressures, and comparatively weak intellectual-property protection in China. China trial funding and supply arrangements depended on the collaboration with Guangxi Wuzhou Pharmaceuticals.
- The auditor issued an unqualified opinion on the financial statements, but did not audit internal control effectiveness. Management concluded disclosure controls and internal control over financial reporting were ineffective as of June 30, 2016, citing a material weakness involving complex, non-routine financial instrument accounting and a prior-period non-material error. The filing says earlier periods had been restated.
Important facts for investors to verify
- Confirm the issuer and period: the supplied document is DelMar’s FY2016 10-K, not a Tuhura filing or 2015 Q4 report.
- Assess actual cash runway and financing needs against the planned clinical-trial schedule; management’s beyond-twelve-month estimate was not a guarantee.
- Review the full Series B preferred-stock and royalty terms, conversion dilution, outstanding warrants, and other potential share issuance.
- Evaluate the underlying clinical data and trial design supporting the 8.35-month survival claim, including the absence of a control group.
- Review the control weaknesses and prior restatements, and confirm whether remediation was sustained in later filings.
- Note apparent inconsistencies in the supplied text: one MD&A passage gives a loss of $8,854,364, while the audited statements report $8,864,864; the audited balance sheet reports accumulated deficit of $32,237,859, while another passage gives $32,227,359. Verify these figures against the filed statements and any amendments.